NCT05525234

A Study of Thalidomide in the Treatment of Refractory Uremic Pruritus

A Prospective, Randomized, Double-blind, Placebo-controlled Study of Thalidomide in the Treatment of Refractory Uremic Pruritus

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: RenJi Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety and efficacy of thalidomide in the treatment of refractory uremic pruritus in maintenance hemodialysis patients.

Detailed description

A prospective, randomized, double-blind, placebo-controlled study was conducted to explore the efficacy and safety of thalidomide in the treatment of refractory urmia pruritus.

Conditions

• Haemodialysis
• Uremic Pruritus
• Thalidomide

Interventions

Type	Name	Description
DRUG	Thalidomide	Start with oral thalidomide at 50mg/day, increase or decrease the dose according to itching relief, the maximum dose is 100mg/day
DRUG	Placebo	Start with oral placebo at 50mg/day, increase or decrease the dose according to itching relief, the maximum dose is 100mg/day

Timeline

• Start date: 2022-09-15
• Primary completion: 2022-12-31
• Completion: 2023-01-31
• First posted: 2022-09-01
• Last updated: 2022-09-01